Evidence map›Paper›PMID 34535979›Full record

Trial reportESC heart failure2021

Design of a multifaceted strategy based on automated text messaging in patients with recent heart failure admission.

Luis E Rohde, Conrado R Hoffmann Filho, Marciane M Rover, Eneida Rejane Rabelo-Silva, Letícia Lopez, Luiz C S Passos, Odilson M Silvestre, Silvia M Martins, José A de Figueiredo Neto, Fábio S Silveira and 15 more

Abstract readMulticenter StudyRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in ESC heart failure, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Trial
  3. Trial
  4. Observational
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

25 authors.

Luis E RohdeServiço de Cardiologia, Hospital Moinhos de Vento, R. Ramiro Barcelos, 910 - Moinhos de Vento, Porto Alegre, 90035-000, Brazil.
Conrado R Hoffmann FilhoHospital Regional Hans Dieter Schmidt, Joinville, Brazil.
Marciane M RoverInstituto de Cardiologia/ Fundação Universitária de Cardiologia- Porto Alegre/RS., Porto Alegre, Brazil.
Eneida Rejane Rabelo-SilvaHeart Failure Clinic, Hospital de Clinicas de Porto Alegre and Nursing School, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil.
Letícia LopezHospital Clínico San Carlos, Madrid, Spain.
Luiz C S PassosHospital Ana Nery, Salvador, Brazil.
Odilson M SilvestreFederal University of Acre, Rio Branco, Brazil.
Silvia M MartinsPronto-Socorro Cardiológico Universitário de Pernambuco - Prof. Luiz Tavares, Recife, Brazil.
José A de Figueiredo NetoHospital Universitário da Universidade Federal do Maranhão, São Luiz, Brazil.
Fábio S SilveiraClínica do Coração de Aracaju, Aracaju, Brazil.
Manoel F CanesinHospital Universitário da Universidade Estadual de Londrina, Londrina, Brazil.
Marcus V SimõesHospital das Clínicas da Faculdade de Medicina de Ribeirão Preto da Universidade de São Paulo, Ribeirão Preto, Brazil.
Fábio Akio NishijukaHospital Naval Marcílio Dias, Rio de Janeiro, Brazil.
Eduardo G BertoldiHospital Escola Universidade Federal de Pelotas, Pelotas, Brazil.
Luiz C DanzmannHospital Universitário de Canoas da Universidade Luterana do Brasil, Canoas, Brazil.
Ricardo Mourilhe-RochaHospital Universitário Pedro Ernesto da Universidade do Estado do Rio de Janeiro, Rio de Janeiro, Brazil.
Ellen Hettwer MagedanzHospital São Lucas da PUCRS, Porto Alegre, Brazil.
Mauro EstevesSanta Casa de Votuporanga, Votuporanga, Brazil.
Fábio M de CastilhoHospital das Clínicas da Universidade Federal de Minas Gerais, Belo Horizonte, Brazil.
Miguel M Fernandes-SilvaQuanta Diagnóstico por Imagem, Curitiba, Brazil.
Luiz E F RittInstituto D'or de Pesquisa e Ensino (IDOR) and Hospital Cárdio Pulmonar, Salvador, Brazil.
Mariana BlacherServiço de Cardiologia, Hospital Moinhos de Vento, R. Ramiro Barcelos, 910 - Moinhos de Vento, Porto Alegre, 90035-000, Brazil.
Rafael M SoaresHCor Research Institute, R. Des. Eliseu Guilherme, 147 - Paraíso, São Paulo, 04004-030, Brazil.
Alexandre B CavalcantiHCor Research Institute, R. Des. Eliseu Guilherme, 147 - Paraíso, São Paulo, 04004-030, Brazil.
Felix RamirezHCor Research Institute, R. Des. Eliseu Guilherme, 147 - Paraíso, São Paulo, 04004-030, Brazil.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimsTo evaluate a telemonitoring strategy based on automated text messaging and telephone support after heart failure (HF) hospitalization. METHODS AND

resultsThe MESSAGE-HF study is a prospective multicentre, randomized, nationwide trial enrolling patients from 30 clinics in all regions of Brazil. HF patients with reduced left ventricular ejection fraction (<40%) and access to mobile phones are eligible after an acute decompensated HF hospitalization. Patients meeting eligibility criteria undergo an initial feasibility text messaging assessment and are randomized to usual care or telemonitoring intervention. All patients receive a HF booklet with basic information and recommendations about self-care. Patients in the intervention group receive four daily short text messages (educational and feedback) during the first 30 days of the protocol to optimize self-care; the feedback text messages from patients could trigger diuretic adjustments or a telephone call from the healthcare team. After 30 days, the frequency of text messages can be adjusted. Patients are followed up after 30, 90, and 180 days, with final status ascertained at 365 days by telephone. Our primary endpoint is the change in N-terminal pro-brain natriuretic peptide (NT-proBNP) levels after 180 days. Secondary endpoints include changes in NT-proBNP after 30 days; health-related quality of life, HF self-care, and knowledge scales after 30 and 180 days; and a composite outcome of HF hospitalization and cardiovascular death, adjudicated by a blinded and independent committee.

conclusionsThe MESSAGE-HF trial is evaluating an educational and self-care promotion strategy involving a simple, intensive, and tailored telemonitoring system. If proven effective, it could be applied to a broader population worldwide.

Indexed as

Heart FailureText MessagingHospitalizationHumansProspective StudiesQuality of LifeStroke VolumeVentricular Function, LeftHeart failureNatriuretic peptideTelemonitoring

Identifiers

PMID34535979
PMCPMC8712788

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.